Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of Interim Results

21st Apr 2021 12:21

RNS Number : 1939W
UDG Healthcare Public Limited Co.
21 April 2021
 

 

 

UDG Healthcare plc

Notice of Interim Results

 

UDG Healthcare plc (LSE: UDG), a leading international healthcare services provider, will be announcing its half year results for the six months ended 31 March 2021 on the morning of Tuesday 18 May 2021.

 

Brendan McAtamney, Chief Executive Officer, Nigel Clerkin, Chief Financial Officer, and Ryan Quigley, Chief Operating Officer will host a virtual presentation for analysts and investors to discuss the company's half year results and provide an update on each of the Group's divisions, followed by a Q&A.

 

Date:

Tuesday 18 May 2021

 

Time:

 

 

The video webcast will commence at 8.30am, and be followed by a live audio Q&A. Please dial-in at 8.15am.

 

Webcast registration link:

 

https://secure.emincote.com/client/udghealthcare/udg008

Conference call registration link:

https://secure.emincote.com/client/udghealthcare/udg008/vip_connect

 

 

Please note: If you wish to ask a question during the live Q&A, please dial into the conference call, as participants on the webcast will be in listen-only mode and therefore unable to ask questions.

 

For further information, please contact:

UDG Healthcare plc

Keith Byrne

 

Head of Investor Relations, Strategy & Corporate Communications

 

Tel: +353-1-468-9000

 

 

 

Powerscourt

 

Lisa Kavanagh / Jack Hickey / Eavan Gannon / Ella Morris

 

[email protected]

 

 

 

About UDG Healthcare plc:

 

UDG Healthcare plc (LON: UDG) is a FTSE 250 global leader in healthcare advisory, marketing, communications, strategic engagement, patient solutions and packaging services. UDG employs 9,000 people across operations in 29 countries, delivering services in over 50 countries.

Operating across two divisions, Ashfield and Sharp, UDG provides outsourced services to over 300 healthcare companies from large pharmaceutical to small biotech companies.

Ashfield is a global integrated healthcare services partner, operating across three business areas: Ashfield Advisory, Ashfield Engage and Ashfield Health. The division enables its healthcare clients to bring their products to market, supporting them through every stage of the product lifecycle, to improve the lives of patients. Ashfield offers a breadth of services, developed organically and through acquisition, across strategic consulting, benchmarking, commercialisation, customer engagement, events, marketing and communications.

Sharp is a global leader in contract commercial packaging, clinical, manufacturing and technology services for the pharmaceutical and biotechnology industries, operating from eight state-of-the-art facilities in the US and Europe.

For more information, please go to: www.udghealthcare.com 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORSESFFFEFSEEL

Related Shares:

UDG.L
FTSE 100 Latest
Value8,275.66
Change0.00